Skip to main content

25 publications

Name Date Type Actions

Sales 3rd quarter 2023: 136M€

The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories.

26/10/2023 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - September 2023

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

04/10/2023 Voting rights

Sustainable development, an integral part of Vetoquinol

Vetoquinol's corporate vision underlines its ambition for its entire ecosystem. This vision creates a dynamic for sustainable development by stating that by 2033 the company will be "the most agile animal health laboratory where employees, experts, partners, and customers work together to create customized solutions dedicated to animal health for a better planet".

13/09/2023 Press releases communication

Monthly information regarding the total number of voting rights and shares making of the share capital - August 2023

As per articles L233-8-II of « Code de Commerce » and 223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

12/09/2023 Voting rights

2023 HALF-YEAR RESULTS

Sales: €256m (-5.4% as reported)
Essentials products sales: €151m (59% of Group sales)
Net income - Group share: €32m (12.6% of sales)
EBITDA*: €54m (20.9% of sales)
Cash-flow generation: €31m

07/09/2023 Public releases

Monthly information regarding the total number of voting rights - July 2023

As per articles L233‐8‐II of « Code de Commerce » and  223.16 of the «Reglement Général de L’Autorité des Marchés Financiers »

22/08/2023 Voting rights

Mastaplex and Vetoquinol announce distribution agreement

Mastaplex Ltd (New Zealand, unlisted) and Vetoquinol (VETO: France Euronext) are pleased to announce an extension of their exclusive distribution agreement for Mastatest..

27/07/2023 Press releases communication

Growth driven by innovation

Ever since the company was founded in 1933, innovation has been a major component of Vetoquinol's development strategy.

13/06/2023 Press releases communication

3rd generation appointed chairman of the board of directors of VETOQUINOL SA

At the Combined General Meeting it was also announced that Mr. Etienne Frechin will resign as Chairman of the Board of Vetoquinol, effective 1st July 2023. Mr. Etienne Frechin will remain a Director of the company, hence continuing to share his broad experience. On 25 May 2023, the Board of Directors appointed Mr. Matthieu Frechin, Chief Executive Officer of the Group, as Chairman of the Board of Directors of Vetoquinol effective 1st July 2023.

25/05/2023 Press releases communication

Essential products

Essential products for the most common needs

27/04/2023 Press releases communication